CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Resverlogix Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Resverlogix Corp
300-4820 Richard Rd SW
Phone: (403) 254-9252p:403 254-9252 CALGARY, AB  T3E 6L1  Canada Ticker: RVXRVX

Business Summary
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer, Secretary Donald J.Mccaffrey 4/4/2016 4/25/2003
Chief Financial Officer A. BradCann 10/26/2009 10/26/2009
Senior Vice President - Medical Affairs Jan O.Johansson 3/1/2004 3/1/2004
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Resverlogix Inc.
RVX

General Information
Number of Employees: 19 (As of 12/31/2022)
Outstanding Shares: 273,448,855 (As of 3/13/2024)
Stock Exchange: TSE
Fax Number: (403) 254-9252


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, March 18, 2024